...ALK fusion, ROS1 rearrangements, RET fusions, or MET exon 14 skipping mutations where there are standard of care therapy options available....

...ALK or ROS1 gene rearrangements, BRAF V600E mutation, or NTRK gene fusions....

...Prior receipt of at least two prior cycles of platinum-based chemotherapy given concurrently with radiotherapy (cCRT); or at least two prior cycles of platinum-based chemotherapy given prior to radiotherapy (sCRT) The RT component in the cCRT or sCRT must have been at a total dose of radiation of 60 (± 10%) Gy (54 Gy to 66 Gy) administered by intensity-modulated radiotherapy (preferred) or three dimension (3D)-conforming technique No disease progression during or following platinum-based cCRT or sCRT Life expectancy ≥ 12 weeks Documented tumor PD-L1 status Eastern Cooperative Oncology Group Performance Status of 0, 1, or 2• Adequate hematologic and end-organ function• For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, during the treatment period and for at least 90 days after the final dose of alectinib or durvalumab (Cohort A1 only) For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, during the treatment period, and for at least 35 days after the final dose of entrectinib, or 90 days after the final dose of durvalumab (Cohort A2 only) For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agreement to refrain from donating eggs, during the treatment period, and for at least 14 days after the final dose of pralsetinib, or at least 90 days after the final dose of durvalumab (Cohort A3 only) For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm during the treatment period and for least 90 days after the final dose of alectinib or durvalumab (Cohort A1 only) For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom plus an additional contraception method, and agreement to refrain from donating sperms, during the treatment period and for at least 3 months after the final dose of entrectinib or final dose of durvalumab Cohort A2 only) For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, during the treatment period and for at least 7 days after the final dose of pralsetinib and at least 90 days after the final dose of durvalumab (Cohort A3 only) Ability to swallow entrectinib intact, without chewing, crushing, or opening the capsules (Cohort A2 only) Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen Documented ALK fusion positivity (Cohort A1 only) Documented ROS1 fusion positivity (Cohort A2 only) Documented RET fusion positivity (Cohort A3 only`•Age >=18 years•Body weight >=30 kg•Whole-body positron emission tomography/computed tomography scan (PET/CT) performed prior and within 42 days of the first dose of cCRT or sCRT•Histologically or cytologically documented locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology (Version 8, American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system (Amin et al. ...

...we identified 134 patients who were treated with chemoradiation followed by durvalumab for NSCLC. We segregated patients with driver mutations to targetable (EGFR, ALK translocation, ROS1 fusion, MET exon 14 skipping, RET fusion, and/or BRAF) (N = 24) and those driven by canonical KRAS mutations (N = 26)....Patients with driver mutations had significantly worse median PFS compared to those without driver mutations (8.9 mo vs 26.6 mo; HR 2.62 p < 0.001). Patients with KRAS mutations had particularly poor PFS (Median 7.9 mo, HR 3.34, p < 0.001), while patients with targetable driver mutations trended to worse PFS (Median 14.5 mo, HR 1.96, p = 0.056).